Rigel Pharmaceuticals (RIGL) — Titan Protect Analysis

RIGL

Rigel Pharmaceuticals

Healthcare · ·

$29.93

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$554M

Total market value of the company

Trailing P/E

1.55

Very cheap relative to earnings

Forward P/E

6.53

Based on estimated future earnings — lower means cheaper

Rev Growth

+10.3%

Year-over-year revenue change

Profit Margin

121.5%

How much profit the company keeps from each dollar of revenue

ROE

174.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$50.00

+67% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 5 analysts covering this stock

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (I

https://www.rigel.com

Country: United States Employees: 172 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.096

Excellent risk-adjusted returns

Kelly Fraction

0.0815

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.523

Returns exceed worst-case losses — strong risk profile

Annual Return

76.3%

Historical annualised return based on price data

Max Drawdown

-50.1%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.20

Moves slightly more than the broader market

52W High

$52.24

43% below the year high

52W Low

$18.14

65% above the year low

Avg Volume

396,904

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$19.29

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

11.43

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

81.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

20.2%

Profit from core operations before interest and tax

Free Cash Flow

$79M

Positive — the business generates more cash than it spends

Revenue (TTM)

$300M

Total revenue over the last 12 months

Net Income

$364M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$81.00

Target Median

$50.00

Target Low

$38.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go